<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949778</url>
  </required_header>
  <id_info>
    <org_study_id>BS-AIO-2015-QL-block</org_study_id>
    <nct_id>NCT02949778</nct_id>
  </id_info>
  <brief_title>Quadratus Lumborum Block for Abdominoplasty</brief_title>
  <official_title>Quadratus Lumborum Block for Perioperative Analgesia in Patients Treated With Abdominoplasty: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded, randomized, controlled, phase IV intervention trial. Both groups will receive
      a quadratus lumborum Block (QL), using ropivacaine 3.75 mg/mL in the intervention group, and
      sterile sodium chloride in the control group. The aim of study is to investigate the effect
      of a QL Block on the perioperative pain during postbariatric abdominoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2016</start_date>
  <completion_date type="Actual">December 13, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>total opioid consumption the first 24 postoperative hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Abdominoplasty</condition>
  <arm_group>
    <arm_group_label>Ropivacaine 3.75mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QL-block using 20 mL ropivacaine 3.75mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride 9 mg/mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>QL-block using 20 mL sterile sodium chloride 9 mg/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>QL-block</intervention_name>
    <description>Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied</description>
    <arm_group_label>Ropivacaine 3.75mg/mL</arm_group_label>
    <arm_group_label>Sodium chloride 9 mg/mL</arm_group_label>
    <other_name>Quadratus lumborum block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine 3.75mg/ml administered in QL-block as active treatment</description>
    <arm_group_label>Ropivacaine 3.75mg/mL</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Sodium chloride 9mg/mL administered in QL-Block as placebo</description>
    <arm_group_label>Sodium chloride 9 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists Physical Classification Status (ASA) I-II

          -  Age 18 to 64

          -  Weight above or equal to 60 kg

          -  Scheduled for post-bariatric surgery with standard full abdominoplasty performed by Dr
             Fr√∏yen

          -  Patient is expected able to cooperate during the treatment and follow up.

          -  Signed informed consent obtained and documented according to the International
             Conference on Harmonization (ICH) good clinical practice (GCP), and national/local
             regulations.

        Exclusion Criteria:

          -  A history of anaphylactic shock

          -  Cardiovascular disease other than hypertension and/or hyperlipidemia

          -  Known allergy to ropivacaine or morphine

          -  A history of chronic pain

          -  Psychiatric comorbidity

          -  Scheduled opioid pain medication or neuroleptic drugs

          -  Coagulation disorders or treatment with platelet inhibitors

          -  Pregnancy or breastfeeding

          -  Treatment with class III antiarrhythmics, sertindole, ziprasidone, amisulpride,
             ceritinib, hydroxyzine, fluvoxamine

          -  Any medical contraindication to the study intervention by the attending anaesthetist
             or surgeon (to be specified in screening form).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thor Wilhelm Bjelland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vestre Viken HT, Baerum Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vestre Viken HT, Baerum Hospital</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Requires approval by ethics committee and second consent form.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

